obeldesivir   Click here for help

GtoPdb Ligand ID: 12901

Synonyms: ATV-006 | ATV006 | compound 5c [PMID: 34450570] | GS-5245 | GS5245
Compound class: Synthetic organic
Comment: Obeldesivir (GS-5245) is an orally bioavailable investigational nucleoside (ATP analogue) antiviral compound [4]. It is an ester prodrug of the predominant remdesivir metabolite GS-441524 [2]. As an inhibitor of viral RNA-dependent RNA polymerase (RdRP) it is likely to have activity against a range of filoviruses, paramyxoviruses, and coronaviruses, including SARS-CoV-2. Postexposure efficacy against SARS-CoV-2 in humans, and Marburg virus and Ebola virus infections (in nonhuman primates) has been reported [1-3,5].

obeldesivir is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 10
Hydrogen bond donors 3
Rotatable bonds 5
Topological polar surface area 153.76
Molecular weight 361.35
XLogP -1.68
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CC(C)C(=O)OC[C@@H]1[C@H]([C@H]([C@](C#N)(C2=CC=C3C(=NC=NN32)N)O1)O)O
Isomeric SMILES CC(C)C(=O)OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O
InChI InChI=1S/C16H19N5O5/c1-8(2)15(24)25-5-10-12(22)13(23)16(6-17,26-10)11-4-3-9-14(18)19-7-20-21(9)11/h3-4,7-8,10,12-13,22-23H,5H2,1-2H3,(H2,18,19,20)/t10-,12-,13-,16+/m1/s1
InChI Key YIHPGVCWGSURHO-VSBTWAGUSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
GS-5245 is in clinical development as a COVID-19 therapeutic.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05996744 Study of Obeldesivir in Children and Adolescents With COVID-19 Phase 2/Phase 3 Interventional Gilead Sciences
NCT05603143 Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness Phase 3 Interventional Gilead Sciences
NCT05715528 Study of Obeldesivir in Nonhospitalized Participants With COVID-19 Phase 3 Interventional Gilead Sciences